Work with thought leaders and academic experts in Molecular Medicine
Companies can greatly benefit from working with experts in the field of Molecular Medicine. These researchers possess in-depth knowledge and skills that can contribute to various aspects of a company's operations. They can provide valuable insights and expertise in areas such as drug discovery and development, personalized medicine, genomics, biomarker identification, and therapeutic interventions. By collaborating with Molecular Medicine experts, companies can accelerate their research and development processes, improve the effectiveness of their products and services, and stay at the forefront of scientific advancements. Additionally, these collaborations can lead to the identification of new business opportunities, partnerships, and potential commercialization of scientific discoveries.
Researchers on NotedSource with backgrounds in Molecular Medicine include Dr. Sakshi Kabra Malpani, Dr. Everson A Nunes, Ph.D., Regan Hamel, Burcu Vitrinel, Ph.D., Dr. David Siderovski, Ph.D., Aimee Eggler, Keisha Walters, Ping Luo, Elvira Forte, and Garrett A. Perchetti, Research Scientist - Virology.
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Other Research Expertise (39)
About
Most Relevant Publications (1+)
97 total publications
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets / Mar 30, 2017
Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345
See Full Profile
Regan Hamel
Senior bioinformatics scientist, specializing in single cell omics in the context of cellular reprogramming and neuroinflammation
Most Relevant Research Expertise
Other Research Expertise (12)
About
Most Relevant Publications (1+)
12 total publications
Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice
Molecular Therapy / Dec 01, 2020
Braga, A., Bandiera, S., Verheyen, J., Hamel, R., Rutigliani, C., Edenhofer, F., Smith, J. A., & Pluchino, S. (2020). Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice. Molecular Therapy, 28(12), 2677–2690. https://doi.org/10.1016/j.ymthe.2020.08.001
See Full Profile
Dr. David Siderovski, Ph.D.
Professor of Computational Pharmacology; Chair of HSC SBS Dept. of Pharmacology & Neuroscience
Most Relevant Research Expertise
Other Research Expertise (25)
About
Most Relevant Publications (8+)
94 total publications
G-protein signaling: back to the future
Cellular and Molecular Life Sciences / Mar 01, 2005
McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P., & Willard, F. S. (2005). G-protein signaling: back to the future. Cellular and Molecular Life Sciences, 62(5), 551–577. https://doi.org/10.1007/s00018-004-4462-3
Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets
Pharmacological Reviews / Jul 07, 2011
Kimple, A. J., Bosch, D. E., Giguère, P. M., & Siderovski, D. P. (2011). Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets. Pharmacological Reviews, 63(3), 728–749. https://doi.org/10.1124/pr.110.003038
Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights
Molecular Pharmacology / Apr 12, 2007
Johnston, C. A., & Siderovski, D. P. (2007). Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights. Molecular Pharmacology, 72(2), 219–230. https://doi.org/10.1124/mol.107.034348
Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors
Molecular Pharmacology / Mar 22, 2006
Hains, M. D., Wing, M. R., Maddileti, S., Siderovski, D. P., & Harden, T. K. (2006). Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors. Molecular Pharmacology, 69(6), 2068–2075. https://doi.org/10.1124/mol.105.017921
The G DIMER as a NOVEL SOURCE of SELECTIVITY in G-Protein Signaling: GGL-ing AT CONVENTION
Molecular Interventions / Aug 01, 2004
Jones, M. B. (2004). The G DIMER as a NOVEL SOURCE of SELECTIVITY in G-Protein Signaling: GGL-ing AT CONVENTION. Molecular Interventions, 4(4), 200–214. https://doi.org/10.1124/mi.4.4.4
G protein signaling in the parasite Entamoeba histolytica
Experimental & Molecular Medicine / Mar 22, 2013
Bosch, D. E., & Siderovski, D. P. (2013). G protein signaling in the parasite Entamoeba histolytica. Experimental & Molecular Medicine, 45(3), e15–e15. https://doi.org/10.1038/emm.2013.30
Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells
Journal of Pharmacology and Experimental Therapeutics / Oct 25, 2013
Holden, N. S., George, T., Rider, C. F., Chandrasekhar, A., Shah, S., Kaur, M., Johnson, M., Siderovski, D. P., Leigh, R., Giembycz, M. A., & Newton, R. (2013). Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 348(1), 12–24. https://doi.org/10.1124/jpet.113.204586
The GoLoco Motif: Heralding a New Tango Between G Protein Signaling and Cell Division
Molecular Interventions / Apr 01, 2002
Kimple, R. J. (2002). The GoLoco Motif: Heralding a New Tango Between G Protein Signaling and Cell Division. Molecular Interventions, 2(2), 88–100. https://doi.org/10.1124/mi.2.2.88
See Full Profile
Aimee Eggler
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Expertise
Other Research Expertise (18)
About
Most Relevant Publications (3+)
25 total publications
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding
Bioorganic & Medicinal Chemistry Letters / Nov 01, 2013
Turlington, M., Chun, A., Tomar, S., Eggler, A., Grum-Tokars, V., Jacobs, J., Daniels, J. S., Dawson, E., Saldanha, A., Chase, P., Baez-Santos, Y. M., Lindsley, C. W., Hodder, P., Mesecar, A. D., & Stauffer, S. R. (2013). Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorganic & Medicinal Chemistry Letters, 23(22), 6172–6177. https://doi.org/10.1016/j.bmcl.2013.08.112
Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
Journal of Medicinal Chemistry / Jan 03, 2013
Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., Mielech, A. M., Baker, S. C., Lindsley, C. W., Hodder, P., Mesecar, A., & Stauffer, S. R. (2013). Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. Journal of Medicinal Chemistry, 56(2), 534–546. https://doi.org/10.1021/jm301580n
Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds
Molecules / Apr 03, 2000
Peterson, C., Tsao, R., Eggler, A., & Coats, J. (2000). Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds. Molecules, 5(12), 648–654. https://doi.org/10.3390/50400648
See Full Profile
Keisha Walters
University of Arkansas
Most Relevant Research Expertise
Other Research Expertise (34)
About
Most Relevant Publications (1+)
102 total publications
Bioluminescent magnetic nanoparticles as potential imaging agents for mammalian spermatozoa
Journal of Nanobiotechnology / Mar 17, 2016
Vasquez, E. S., Feugang, J. M., Willard, S. T., Ryan, P. L., & Walters, K. B. (2016). Bioluminescent magnetic nanoparticles as potential imaging agents for mammalian spermatozoa. Journal of Nanobiotechnology, 14(1). https://doi.org/10.1186/s12951-016-0168-y
See Full Profile
Ping Luo
Bioinformatics Specialist at Princess Margaret Cancer Centre with experience in deep learning
Most Relevant Research Expertise
Other Research Expertise (21)
About
Most Relevant Publications (2+)
23 total publications
deepDriver: Predicting Cancer Driver Genes Based on Somatic Mutations Using Deep Convolutional Neural Networks
Frontiers in Genetics / Jan 29, 2019
Luo, P., Ding, Y., Lei, X., & Wu, F.-X. (2019). deepDriver: Predicting Cancer Driver Genes Based on Somatic Mutations Using Deep Convolutional Neural Networks. Frontiers in Genetics, 10. https://doi.org/10.3389/fgene.2019.00013
Identifying Disease-Gene Associations With Graph-Regularized Manifold Learning
Frontiers in Genetics / Apr 02, 2019
Luo, P., Xiao, Q., Wei, P.-J., Liao, B., & Wu, F.-X. (2019). Identifying Disease-Gene Associations With Graph-Regularized Manifold Learning. Frontiers in Genetics, 10. https://doi.org/10.3389/fgene.2019.00270
See Full Profile
Elvira Forte
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Other Research Expertise (26)
About
Most Relevant Publications (6+)
63 total publications
Serum and supplement optimization
for EU GMP ‐compliance in
cardiospheres cell culture
Journal of Cellular and Molecular Medicine / Jan 20, 2014
Chimenti, I., Gaetani, R., Forte, E., Angelini, F., De Falco, E., Zoccai, G. B., Messina, E., Frati, G., & Giacomello, A. (2014). Serum and supplement optimization for <scp>EU GMP</scp>‐compliance in cardiospheres cell culture. Journal of Cellular and Molecular Medicine, 18(4), 624–634. Portico. https://doi.org/10.1111/jcmm.12210
Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application
Journal of Cellular and Molecular Medicine / May 01, 2010
Gaetani, R., Rizzitelli, G., Chimenti, I., Barile, L., Forte, E., Ionta, V., Angelini, F., Sluijter, J. P. G., Barbetta, A., Messina, E., & Frati, G. (2010). Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. Journal of Cellular and Molecular Medicine, no-no. https://doi.org/10.1111/j.1582-4934.2010.01078.x
Different types of cultured human adult Cardiac Progenitor Cells have a high degree of transcriptome similarity
Journal of Cellular and Molecular Medicine / Oct 14, 2014
Gaetani, R., Feyen, D. A. M., Doevendans, P. A., Gremmels, H., Forte, E., Fledderus, J. O., Ramjankhan, F. Z., Messina, E., Sussman, M. A., Giacomello, A., & Sluijter, J. P. G. (2014). Different types of cultured human adult Cardiac Progenitor Cells have a high degree of transcriptome similarity. Journal of Cellular and Molecular Medicine, 18(11), 2147–2151. Portico. https://doi.org/10.1111/jcmm.12458
Bone marrow‐derived cells can acquire cardiac stem cells properties in damaged heart
Journal of Cellular and Molecular Medicine / Jan 01, 2011
Barile, L., Cerisoli, F., Frati, G., Gaetani, R., Chimenti, I., Forte, E., Cassinelli, L., Spinardi, L., Altomare, C., Kizana, E., Giacomello, A., Messina, E., Ottolenghi, S., & Magli, M. C. (2011). Bone marrow‐derived cells can acquire cardiac stem cells properties in damaged heart. Journal of Cellular and Molecular Medicine, 15(1), 63–71. Portico. https://doi.org/10.1111/j.1582-4934.2009.00968.x
A Chemical Biology Approach to Myocardial Regeneration
Journal of Cardiovascular Translational Research / Mar 22, 2011
Willems, E., Lanier, M., Forte, E., Lo, F., Cashman, J., & Mercola, M. (2011). A Chemical Biology Approach to Myocardial Regeneration. Journal of Cardiovascular Translational Research, 4(3), 340–350. https://doi.org/10.1007/s12265-011-9270-6
Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart
Journal of Cellular and Molecular Medicine / Nov 29, 2020
Forte, E., Panahi, M., Baxan, N., Ng, F. S., Boyle, J. J., Branca, J., Bedard, O., Hasham, M. G., Benson, L., Harding, S. E., Rosenthal, N., & Sattler, S. (2020). Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart. Journal of Cellular and Molecular Medicine, 25(1), 229–243. Portico. https://doi.org/10.1111/jcmm.15937
See Full Profile
Garrett A. Perchetti, Research Scientist - Virology
Research Scientist and MD Candidate in virology with publications on infectious diseases, laboratory medicine, viral genetics, and clinical medicine
Most Relevant Research Expertise
Other Research Expertise (14)
About
Most Relevant Publications (1+)
28 total publications
Predicting infectivity: comparing four PCR‐based assays to detect culturable SARS‐CoV‐2 in clinical samples
EMBO Molecular Medicine / Dec 13, 2021
Bruce, E. A., Mills, M. G., Sampoleo, R., Perchetti, G. A., Huang, M., Despres, H. W., Schmidt, M. M., Roychoudhury, P., Shirley, D. J., Jerome, K. R., Greninger, A. L., & Botten, J. W. (2021). Predicting infectivity: comparing four PCR‐based assays to detect culturable SARS‐CoV‐2 in clinical samples. EMBO Molecular Medicine, 14(2). Portico. https://doi.org/10.15252/emmm.202115290
See Full Profile
Example Molecular Medicine projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Molecular Medicine?
Drug Discovery and Development
A pharmaceutical company can collaborate with a Molecular Medicine expert to identify potential drug targets, design and optimize drug candidates, and conduct preclinical and clinical trials. This collaboration can significantly speed up the drug discovery and development process, leading to the creation of novel and effective therapies.
Personalized Medicine
By working with a Molecular Medicine researcher, a healthcare company can develop personalized treatment strategies based on an individual's genetic makeup, lifestyle, and environmental factors. This approach can improve patient outcomes, minimize adverse effects, and optimize healthcare resources.
Genomics and Precision Medicine
Companies in the biotechnology and diagnostics sectors can collaborate with Molecular Medicine experts to leverage genomic data for disease diagnosis, prognosis, and treatment selection. This collaboration can lead to the development of innovative diagnostic tools, targeted therapies, and precision medicine approaches.
Biomarker Identification
A company focused on biomarker discovery can benefit from collaborating with a Molecular Medicine expert. These researchers can identify and validate biomarkers that can be used for early disease detection, monitoring treatment response, and predicting patient outcomes. Such collaborations can drive the development of diagnostic tests and personalized medicine solutions.
Therapeutic Interventions
Pharmaceutical and biotechnology companies can partner with Molecular Medicine experts to explore novel therapeutic interventions, including gene therapies, RNA-based therapeutics, and targeted drug delivery systems. These collaborations can lead to the development of breakthrough treatments for various diseases and conditions.